menu
    • menu
    [{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IsoTherapeutics Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"2","companyTruncated":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Rhenium-186 Obisbemeda","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IsoTherapeutics Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IsoTherapeutics Group \/ Plus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"IsoTherapeutics Group \/ Plus Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by IsoTherapeutics Group

    Menu

    IsoTherapeutics Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IsoTherapeutics Group

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            IsoTherapeutics Group

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rhenium-186 Obisbemeda

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Plus Expands Agreement with Telix for Rhenium-186 Radioisotope Supply

                            Details : The agreement secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda, a novel injectable radiotherapy.

                            Brand Name : 186RNL

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Rhenium-186 Obisbemeda

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Plus Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IsoTherapeutics Group

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            IsoTherapeutics Group

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MNPR-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe C...

                            Details : IsoTherapeutics will modify Monopar’s proprietary uPAR targeted antibody, MNPR-101, by making conjugates that will attachment of therapeutic radioisotopes supplied by NorthStar, creating a platform of uPAR-targeted RIT candidates to be studied to treat...

                            Brand Name : MNPR-101

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 10, 2020

                            Lead Product(s) : MNPR-101

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth